Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M255Revenue (TTM) $M1.8Net Margin (%)-2,346.5Altman Z-Score3.0
Enterprise Value $M195EPS (TTM) $-1.7Operating Margin %-2,269.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score1.3Pre-tax Margin (%)-2,346.5Higher ROA y-yY
Price/Book4.110-y EBITDA Growth Rate %--Quick Ratio9.3Cash flow > EarningsY
Price/Sales1355-y EBITDA Growth Rate %--Current Ratio9.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-53.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.2ROIC % (ttm)-4,795.8Gross Margin Increase y-yN

Gurus Latest Trades with OCUL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OCUL is held by these investors:



OCUL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-12-15Buy45,300$7.8528.92view
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-06-09Buy10,000$6.751.04view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-11-17Buy10,000$8.2522.67view
Fortune JamesCOO 2015-09-15Sell9,470$17.16-41.03view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-09-14Buy15,000$16.5-38.67view
Versant Venture Capital III, L10% Owner 2015-06-15Sell320,000$22-54view
Warden Charles MDirector, 10% Owner 2015-06-15Sell320,000$22-54view
SVLSF IV, LLC10% Owner 2015-06-10Sell1,119,000$22-54view
Versant Venture Capital III, L10% Owner 2015-06-10Sell427,000$22-54view
Warden Charles MDirector, 10% Owner 2015-06-10Sell427,000$22-54view

Quarterly/Annual Reports about OCUL:

    News about OCUL:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

    More From Other Websites
    Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences Feb 09 2017
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jan 25 2017
    ETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017 Jan 25 2017
    Ocular Therapeutics Sinks Following Secondary Offering Jan 24 2017
    Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock Jan 24 2017
    Ocular Therapeutix, Inc. Announces Public Offering of Common Stock Jan 23 2017
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events Jan 23 2017
    Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After... Jan 23 2017
    ETFs with exposure to Ocular Therapeutix, Inc. : January 9, 2017 Jan 09 2017
    6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017
    Ocular (OCUL) Reports Positive Phase III Data on Eye Drug Jan 05 2017
    Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of... Jan 04 2017
    Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of... Jan 04 2017
    ETFs with exposure to Ocular Therapeutix, Inc. : December 30, 2016 Dec 30 2016
    7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
    How Ocular Therapeutix Inc (OCUL) Stacks Up Against Its Peers Dec 15 2016
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events Dec 14 2016
    ETFs with exposure to Ocular Therapeutix, Inc. : December 8, 2016 Dec 08 2016
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Nov 30 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)